News | June 24, 2009

NAVISCAN to Distribute High-Res Breast PET to Korea, Latin America

June 24, 2009 - Naviscan Inc., a molecular breast imaging (MBI) provider, has entered into a distribution agreement with Hae Dong Co. Ltd. to market and serve Naviscan’s high-resolution organ-specific PET scanner, whose breast application is known as positron emission mammography (PEM), in the Republic of South Korea.

The first unit will be installed at Seoul National University Hospital, where it will be available to physicians and researchers while awaiting Korean FDA approval.

Naviscan manufactures is a commercially available PEM imaging scanner and PEM-guided biopsy system. The scanner uses PET technology to produce tomographic images that allow physicians to visualize breast tumors down to 2 mm, the width of a grain of rice. The scanner is the size of a mammography unit and uses gentle breast immobilization, allowing for greater patient comfort, as well as reducing motion artifact and improving image resolution.

Hae Dong Co. Ltd. is the leader in the Korean market for Radiation Oncology products and Nuclear Medicine. As a distributor of Philips whole-body PET scanners, and producer and distributor of Fluorodeoxyglucose or FDG (the positron-emitting radioactive isotope used in PET), the Naviscan PEM scanner complements Hae Dong’s molecular imaging suite of solutions.

Additional distributorships have been selected in Mexico, Venezuela and Colombia. Naviscan will be launching in those countries by the fourth quarter of 2009.

For more information: www.naviscan.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
News | Artificial Intelligence | May 08, 2019
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to...
Georgia Becomes 38th State With Breast Density Inform Law
News | Breast Density | May 06, 2019
Georgia Gov. Brian Kemp signed breast density inform bill HB62 into law May 3, 2019. The law, which becomes effective...
American Society of Breast Surgeons Issues Risk-based Screening Mammography Guidelines
News | Mammography | May 03, 2019
The American Society of Breast Surgeons (ASBrS) has released the first screening mammography guidelines based on a...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...